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Inﬂuenza A viral infections reached pandemic levels in 1918, 1957, 1968, and, most recently, in 2009 with the emergence of
the swine-origin H1N1 inﬂuenza virus. The development of novel therapeutics or prophylactics for inﬂuenza virus infection is
urgently needed. We examined the evaluation of the anti-inﬂuenza virus (A/WSN/33 (H1N1)) activity of Brazilian green propolis
water extract (PWE) and its constituents by cell viability and real-time PCR assays. Our ﬁndings showed strong evidence that
PWE has an anti-inﬂuenza eﬀect and demonstrate that caﬀeoylquinic acids are the active anti-inﬂuenza components of PWE.
Furthermore, we have found that the amount of viral RNA per cell remained unchanged even in the presence of PWE, suggesting
that PWE has no direct impact on the inﬂuenza virus but may have a cytoprotective activity by aﬀecting internal cellular process.
These ﬁndings indicate that caﬀeoylquinic acids are the active anti-inﬂuenza components of PWE. Above ﬁndings might facilitate
the prophylactic applicationof naturalproducts and the realizationof novel anti-inﬂuenza drugs based on caﬀeoylquinic acids, as
well as further the understanding of cytoprotective intracellular mechanisms in inﬂuenza virus-infected cells.
1.Introduction
Worldwide swine-origin H1N1 inﬂuenza virus infection
became a pandemic in 2009 [1]. Two of the viral proteins,
neuraminidase (NA) and the M2 ion-channel protein, are
the primary targets of current inﬂuenza antiviral drugs [2].
Unfortunately, there is already widespread resistance to both
drug classes [3]. Recently, a novel drug candidate targeting
RNA polymerase has been reported [4]. Despite the recent
advances in inﬂuenza therapies, direct viral drug targets are
generally limited; therefore, we must consider new strategies
in drug development for the mitigation of inﬂuenza virus
infection.
Propolis is a resinous substance that is collected by hon-
eybees from plant sources and is thought to play a protective
role against potential predators. Propolis has been used in
folk medicine and has been reported to possess therapeutic
and prophylactic eﬀects against inﬂammation, heart disease,
diabetes mellitus, hepatotoxicity, and cancer [5, 6]. Antiviral
activity of propolis were demonstrated comprising anti-
BBMV [7], anti-HSV [8–12], anti-poliovirus [13], anti-r
IBDV [14], anti-reovirus [14], anti-HIV [15–17], and so on
[14, 18–20]. There are numerous reports regarding the anti-
inﬂuenza virus activity of propolis [21–24]. However, no
eﬀective constituents have been isolated from propolis for
inﬂuenza virus treatment or prophylaxis.
The constituents of propolis are greatly inﬂuenced by
its production area and plant origin. Currently, propolis
is classiﬁed into many diﬀerent type such as European
(poplar type), Brazilian (Baccharis type, derived from Ale-
crim; Baccharis dracunculifolia (Compositae) [25]), Cuban,
and Taiwanese type [26]. Specially, both poplar type and
Baccharis type of propolis have been deeply studied. In
Japan, Brazilian green propolis, which is Baccharis type
and originates from Minas Gerais, is most popular. In
other words, health supplement utilizing Brazilian green2 Evidence-Based Complementary and Alternative Medicine
propolis occupies mostly in Japanese propolis health food
markettoday.Moreover,recentreportsrevealedthatpropolis
collected from very speciﬁc and limited areas in southern
Brazil has an anti-inﬂuenza eﬀect [24]. Thus we chose the
Brazilian green propolis from Minas Gerais for study.
In this paper, we have identiﬁed the major constituents
with the anti-inﬂuenza virus activity in Brazilian green
propolis and have further investigated the mechanisms of
these activities using a combination of cell viability and real
time PCR assays.
2.Methods
2.1. Cells, Viruses, and Compounds. Madin-Darby canine
kidney cells (MDCK cells) was provided by Professor Hideto
Fukushi, United Graduate School of Veterinary Sciences,
Gifu University. The inﬂuenza A virus strain A/WSN/33
(H1N1) was provided by Prof. Yoshihiro Kawaoka, the Insti-
tute of Medical Science, the University of Tokyo. Minimal
essential medium (MEM, Wako Pure Chemicals, Osaka,
Japan; or Invitrogen, Carlsbad, California), fetal bovine
serum (Equitech-bio, Inc., Kerrville, TX, USA), phosphate
buﬀered saline (PBS) (Gibco, Rockville, MD), penicillin and
streptomycin (Gibco, Rockville, MD), and Cell Counting
Kit-8 (Dojindo, Kumamoto, Japan) were used. Water extract
of Brazilian green propolis, which was collected in the state
of Minas Gerais (PWE, product name: Proapi), was supplied
by API Co., Ltd. Chlorogenic acid and caﬀeic acid were
purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo,
Japan), and quinic acid was purchased from Nacalai Tesque,
Inc. (Kyoto, Japan). 3,4-Dicaﬀeoylquinic acid (3,4-diCQA),
3,5-dicaﬀeoylquinic acid (3,5-diCQA), 4,5-dicaﬀeoylquinic
acid (4,5-diCQA), and 3,4,5-tricaﬀeoylquinic acid (3,4,5-
triCQA) were isolated from the propolis, as previously
described [27]. The 3,4-dicaﬀeoylquinic acid (3,4-diCQA),
3,5-dicaﬀeoylquinic acid (3,5-diCQA), 4,5-dicaﬀeoylquinic
acid (4,5-diCQA), and 3,4,5-tricaﬀeoylquinic acid (3,4,5-
triCQA) were 85.5%, 90.0%, 51.4%, and 87.4% pure,
respectively. The purity of 4,5-diCQA has decreased rapidly
by degradation during storage. Its purity was 90% or more
just after the puriﬁcation.
2.2. In Vitro Anti-Inﬂuenza Virus Assay and Cytotoxicity
Assay. To assess anti-inﬂuenza activity, MDCK cells (2 ×
105/well) were culturedin MEM (Wako) that contained 10%
fetal bovine serum, 60U/mL of penicillin, and 60μg/mL of
streptomycin for 24hrs on 96-well plates, washed with PBS,
and infected with 20 to 200 TCID50 A/WSN/33 virus in the
presence or absence of compounds. Compounds were added
almost simultaneously in an assay medium, MEM (Invitro-
gen) that was supplemented with 1% BSA, 1% DMSO, and
6.25μg/mL trypsin. Cell culture were maintained without
medium exchange at 37◦C, 5% CO2 for 48hrs. Culture
supernatants were collected 48hrs after infection for real
time PCR assay. Remaining cells were then washed twice
with PBS, and the antiviral eﬀects of the compounds were
evaluated using a cell viability assay (WST-8 (2-(2-methoxy-
4-nitrophenyl)-3- (4-nitrophenyl)- 5-(2,4-disulfophenyl) -
2H tetrazolium monosodium salt), Cell Counting Kit-8) to
measure the probability of survival [28]. The EC50 (half
maximal eﬀective concentration) value on the cell survival is
determined by curve ﬁtting method using GraphPad Prism
for Windows (Version 5.02, GraphPad Software, Inc.) under
a nonlinear regression curve ﬁtting in which the maximum
response value was set to 100% or less. Cytotoxicity was
assessed using assays with no viral infection.
2.3. RNA Extraction and Quantitative Real-Time PCR Assay.
Viral genomic RNA was extracted from the supernatants
of the culture using the High Pure Viral RNA Kit (Roche
Diagnostics, Mannheim, Germany) according to the man-
ufacture’s protocol. A 200-μL aliquot of supernatant was
dissolved in a lysis buﬀer that contained poly-A that was
bound to a glass ﬁber column. RNA was eluted from
the column using 50μL of nuclease-free water. cDNA was
synthesized from 2μLoftheeluatebyusingaPrimeScriptRT
Reagent Kit (Perfect Real Time, Takara Bio Inc., Otsu, Japan)
and random hexamer as reverse transcription (RT) primers
according to the manufacture’s protocol. Quantitative real-
timePCRforH1N1wasperformed.TheRTreactionproduct
wasampliﬁed byusing SYBRPremixExTaq (TakaraBioInc.,
Otsu, Japan) and Thermal Cycler Dice Real Time (Takara
B i oI n c . ,O t s u ,J a p a n )a c c o r d i n gt ot h em a n u f a c t u r e r ’ s
protocol. H1N1-speciﬁc primers were selected using Primer
Express Software (PE Applied Biosystems) and based on the
polymerase basic protein 1 gene (PB1). The sequences of
t h ep r i m e rs e t si n c l u d e d5  -GATGGACAACAAACACCG-
AAACT-3  as the forward primer and 5 -TACACAATG-
TTTGGGCATAACC-3  as the reverse primer. Quantitative
RNA levels relative to the control, which were derived from
the supernatant of the culture by adding vehicle and H1N1-
expressing infected cells, were estimated using the standard
curve of serial dilution.
2.4. Statistical Analysis. Data were analyzed by one-way
analysis of variance (ANOVA), followed by a Bonferroni
multiple comparison test using JSTAT, version 12.6, for
Windows (Masato Sato, Japan).
3.Results
3.1. MajorComponents in PWE. Figure 1 shows the chemical
structure of several caﬀeoylquinic acids that are the primary
componentsofthepropoliswaterextract(PWE) andinclude
chlorogenic acid, 3,4-diCQA, 3,5-diCQA, 4,5-diCQA, and
3,4,5-triCQA. Caﬀeoylquinic acids are phenolic acids and
esters of polyphenolic caﬀeic acid (its number is from one
t ot h r e e )a n dq u i n i ca c i d( b o t ha l s os h o w ni nF i g u r e1(a)).
The percentage concentration of each component (Table 1)
hasbeenalreadyreported[27,29].Concentrationsofchloro-
genic acid, 3,4-diCQA, and 3,5-diCQA acid are relatively
high, that is, 2.7%–3.6%, 3.3%–6.1%, and 4.3%–4.9%,
respectively. Other components of PWE such as p-coumaric
acid [27, 29] were not shown here.
3.2. Antiviral Eﬀects of Each Ingredient in The PWE. The
overall impact of the PWE on the cell survival rate in
WSN/33 infected MDCK cells is depicted in Figure 2(a).C e l lEvidence-Based Complementary and Alternative Medicine 3
Table 1: Concentrations and molecular weights of the constituents of Brazilian green propolis [27, 29].
PWE components Content (w/w%) in PWE Molecular weight (g/mol)
Chlorogenic acid 2.7–3.6 354.3
Caﬀeic acid 0.2 180.2
3,5-Dicaﬀeoylquinic acid 4.3–4.9 516.5
3,4-Dicaﬀeoylquinic acid 3.3–6.1 516.5
4,5-Dicaﬀeoylquinic acid —# 516.5
3,4,5-Tricaﬀeoylquinic acid 0.2 678.6
Quinic acid —# 192.2
#: data not available.
HOOC
HO
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HO
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Quinic acid: R1 = R2 = R3 = H Caﬀeoyl (caﬀeic acid)
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3, 4-dicaﬀeoylquinic acid: R1 = R2
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Figure 1: Chemical structure of the caﬀeoylquinic acids that were derived from the propolis used in this study.
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Figure2:TheantiviraleﬀectofPWEanditscomponentsinMDCKcells infected withinﬂuenzaAvirus.Cell viabilityisplotted asafunction
of the concentration of applied sample (μg/mL). Results are presented as mean value±standard deviation; n = 6. ∗P<. 05 and ∗∗P<. 01 in
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Table 2:The EC50 ofPWEcomponentsdetermined by curve ﬁtting
of the data in Figure 2.
PWE components EC50 (μM)
Chlorogenic acid 341.5#
Caﬀeic acid 191.2#
3,5-Dicaﬀeoylquinic acid 207.8#
3,4-Dicaﬀeoylquinic acid 81.1 ±2.9
4,5-Dicaﬀeoylquinic acid 280.6#
3,4,5-Tricaﬀeoylquinic acid 114.6#
Quinic acid >1561
#: standard error not deterministic.
viability of MDCK cells was inhibited under the presence
of virus. In the presence of 100 to 300μg/mL of the PWE,
the percentage of the cell viability signiﬁcantly (P<. 01)
increased. The EC50 value on the cell survival by PWE
was 183.1 ± 6.0μg/mL (mean ± standard error). We then
investigated the individual ingredients in the PWE so as to
identify the speciﬁc ingredient t h a tw a sr e s p o n s i b l ef o rt h i s
eﬀect. As can be observed in Figures 2(b)–2(h), chlorogenic
acid, 3,4-diCQA, 3,5-diCQA, 4,5-diCQA, 3,4,5-triCQA, and
caﬀeic acid were eﬀective. Quinic acid was ineﬀective. The
EC50 values of the cell survival by each component shows
that 3,4-diCQA was the most potent (EC50 = 81.1μM
(41.9μg/mL)) in the tested compounds (Table 2). We also
tested similar activity of the other components of PWE, such
as p-coumaric acid, artepillin C, baccharin, drupanin, and
kemferide (details not shown). These compounds did not
have any cell surviving activity of viral infected cells (data
not shown). Thus, it is highly probable that 3,4-diCQA is
the predominant chemical that is responsible for the anti-
inﬂuenza eﬀect of the PWE.
3.3. Cell Toxicity of Each Ingredient in The PWE. Chloro-
genic acid, 3,4,5-triCQA, and caﬀeic acid were eﬀective at
100μg/mL; however, at 300μg/mL, the cell survival rate
suddenly dropped to nearly zero, suggesting cell toxicity
at this concentration, as shown in Figures 2(f) and 2(g).
Therefore, we systematically examined the cell toxicities of
the compounds, as shown in Figure 3. Chlorogenic acid,
3,4,5-triCQA, and caﬀeic acid exhibited cell toxicities at
300μg/mL whereas other compounds did not exhibit any
serious toxicity.
3.4. Mechanism of The Antiviral Eﬀect. We measured the rel-
ative amount of viral RNA using real-time PCR. Figure 4(a)
depicts the amount of viral RNA as a function of the
concentration of the PWE. The relative amount of viral RNA
increased as a function of increasing PWE concentration,
possibly due to an increase in the number of surviving
cells. We then obtained the relative amounts of viral RNA
per cell using a ratio of the relative amount of viral
RNA and the cell survival rate, as plotted in Figure 4(b).
Intriguingly, the relative amount of viral RNA per cell
remained almost constant as the PWE concentration was
increased (Figure 4(b)).
4.Discussion
Propolisisknowntohaveseveralbiologicalactivities, includ-
ing antimicrobial [30], antibacterial [31, 32], antiviral [7–
20], and immunomodulatory eﬀects [33–35]. In particular,
the antibacterial and anti-viral eﬀects of propolis have been
known for a long time [36–38], and propolis has also been
reported as an anti-inﬂuenza compound [21–24, 39].
Esanu et al. [22] reported that the slight anti-inﬂuenza
eﬀect of rutin was attributed to glucoside-induced vasodi-
lation, which would favor the penetration of the virus into
the blood stream at the level of the nasal mucosa. In another
report [40], rutinand quercetin,which are bothcomponents
of propolis, were reported to increase the HA titers and mor-
tality ratesofPR8-infected mice whereas NaF decreased both
parameters. In this same report, caﬀeine and adamantane
derivatives were reported to have anti-inﬂuenza activities.
The composition of propolis varies depending on the
plant sources that are accessible to the bees [27, 29]. Incon-
sistencieshaveemergedamong severalreportsusing propolis
from diﬀerentsources, and, therein, these inconsistencies are
most likely attributed to diﬀerences in the chemical prop-
erties of the propolis as a function origin. Here, we used
the most popularly distributed type of propolis in Japan,
Brazilian green propolis that is collected in the Minas Gerais
state throughout this study. Brazilian green propolis-derived
PWE primarily contains polyphenolic compounds, such as
ﬂavones,ﬂavanones, phenolicacids, andphenolicacidesters,
the compositions of which remain relatively constant (data
not shown). It should be noted that the propolis used in this
study does not include quercetin [41].
Here, we demonstrate that PWE and various caf-
feoylquinic acids that are contained in PWE can restore the
viability of MDCK cells that have been infected with
inﬂuenza virus in a dose-dependent manner. Although caf-
feoylquinic acid was reported to have an anti-inﬂuenza eﬀect
[42], our results provide evidence that 3,4-diCQA puri-
ﬁed from propolis has a particularly potent anti-inﬂuenza
activity. Our results also demonstrate that the cause of
the anti-viral activity of the propolis can be attributed to
caﬀeoylquinic acids. Additionally, we found that caﬀeic acid
had an anti-inﬂuenza activity whereas quinic acid did not.
Therefore, the caﬀeoyl group might be an indispensable
moiety in the molecular structure of caﬀeoylquinic acids in
terms of anti-inﬂuenza activity. Moreover, the other PWE
component such as p-coumaric acid, artepillin C, baccharin,
drupanin, and kemferide (not possessing the structure of
caﬀeoylquinic acid) had not the anti-inﬂuenza activity,
Moreover, PWE and caﬀeoylquinic acid did not have any
cytotoxic impact on the eﬀective concentration range for
anti-inﬂuenza activity.
It must be noted that the anti-inﬂuenza activity of PWE
can be only partially explained by compounds tested here
(ref. Tables 1 and 2). Thus it is highly possible that unknown
eﬃcientcompoundsmustbeincludedinPWE. However,the
identiﬁcation of such compounds is deﬁnitely a future task.
T h ep r i m a r yi n t e r e s to ft h ep a p e ri sf o c u s e do nt h e
working mechanisms of the antiviral activities of these
compounds. Therein, the initial question was whether theEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: The cytotoxicities ofPWEandits componentsinMDCK cells.Cell viability isplotted as a functionoftheconcentrationofapplied
sample (μg/mL). Results are presented as mean value ± standard deviation; n = 6. ∗P<. 05 and ∗∗P<. 01 in comparison to 0μg/mL.
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Figure 4: Real-time PCR assay of the PWE-induced antiviral state. (a): The relative amount of viral RNA in a culture supernatant. (b): The
value of A per probability of survival in a WST-8 assay. Results are presented as mean value ± standard deviation; n = 6.
observed antiviral activities are exerted on the virus or the
host cell. To address this, we measured the relative amount
of viral RNA in the cultured cell with and without antiviral
compounds.
Because the relative amount of virus RNA per viable
MDCK cell was not signiﬁcantly diﬀerent between groups
withdiﬀerentcompoundconcentrations, itishighly possible
thatPWEhasnodirecteﬀectonthevirusordoesnotinteract
with viral components.
AlthoughthequantityofmRNAforHA(hemagglutinin)
relative to that of mRNA for glyceraldehyde-3-phosphate
dehydrogenase in inﬂuenza virus-infected MDCK cells de-
creased to less than 10% in the presence of the anti-inﬂuenza
agent ribavirin (5μg/mL), it never decreased in the presence
of 100μg/mL of PWE (data not shown).
These ﬁndings are consistent with previous reports that
propolis extract had no direct impact on herpes simplex
virus but may induce internal cellular changes that can
aﬀect the replication of the virus, for example, through the
interaction with NF-κB[ 43]. Li et al. [44]h a v er e p o r t e d
that dicaﬀeoylquinic acids speciﬁcally bind to the gp120
[45] of RSV and inhibit the virus-cell fusion events in the
early stage of the replication cycle and cell-cell fusion at the
end of the replication cycle [46]. The neuroprotective and
immunomodulatory eﬀects of PWE are also well known
[33–35]. Thus, the anti-inﬂuenza activity of PWE does not
derive from an inhibition of virus replication, as is the case
for a neuraminidase inhibitory drug, but, instead, may be
due to another mechanism, such as an enhancement of cell
resistivity via the activation or inactivation of unknown
cellular processes.6 Evidence-Based Complementary and Alternative Medicine
We do not claim the discovery of a novel anti-inﬂuenza
drug candidate; however, further extensive study of the caf-
feoyl group may direct the development of future novel
anti-inﬂuenza drugs. Therein, it is important to note that
the natural products that are represented by propolis may
haveprophylactic ormoderate anti-inﬂuenza virusactivities.
These observations are also important because the inﬂuenza
virus can easily develop resistance to developed drugs, and
it generally takes a long time for new drugs to be approved
by the FDA. During the long development period, natural
products may be able to satisfy treatment needs. Propolis
may have generalpharmacological value as a natural mixture
and not as a source of new, powerful antiviral compounds
[37].
Our study provides strong evidence that PWE has an
anti-inﬂuenza eﬀect. We have demonstrated that caf-
feoylquinic acids are the active anti-inﬂuenza components
of PWE. By the combination analysis using the cell viability
assay and real-time PCR, it is highly possible that PWE has
no direct eﬀect on the virus or does not interact with viral
components. These ﬁndings could facilitate the application
of natural products as prophylactics or moderate anti-
inﬂuenza agents, as well as structural optimization based
on caﬀeoylquinic acids and a further enhancement of our
understanding of the intracellular process that occur during
inﬂuenza virus infection.
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